Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxepin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.97 |
| ▸ | HTR1A | P08908 | 2/20 | 0.97 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | DRD2 | P14416 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxepin SCHEMBL1281891 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Cidoxepin SCHEMBL29368454 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL29359800 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| E-Doxepin SCHEMBL60287 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL41532 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Cidoxepin SCHEMBL124597 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL29018844 | 0.99 | ALDH1A1 (0.97) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Cidoxepin SCHEMBL684837 | 0.99 | HTR2B (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL31349647 | 0.99 | HTR2B (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B | |
| Doxepin SCHEMBL28054 | 0.99 | HTR2B (1.00) | ALDH1A1KDM4EPMP22RECQLHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| CN-104040719-A | Drug screening method and application thereof | COLD SPRING HARBOR LAB | 2014-09-10 | — | — | CN | disclosed |
| EP-2254564-A1 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | Glaxo Group Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009074607-A1 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | SLC6A4, SLC1A2, SLC6A2 | HRH1 417/4885SLC6A2 3/4885ALDH1A1 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.